Twenty-seven and counting – biosyn’s global expansion strategy

Twenty-seven and counting – biosyn’s global expansion strategy

Developing pharmaceutical-grade trace elements for marketing is a long-term venture: It can take up to decades to go from the trial laboratory to applications in humans. Then comes the total procedure time companies need to invest in applying for and being granted marketing authorization. Now multiply that figure by 27. That would come close to equaling the effort biosyn Arzneimittel GmbH invested in obtaining licenses to sell its products around the globe.

Some of its blockbusters include the likes of IMMUCOTHEL and selenase. No rivalry here, because the company’s flagship brand by far surpasses all other siblings in sales: selenase whose active ingredient is sodium selenite pentahydrate, the inorganic but highly bioavailable form of the essential micronutrient selenium.

Twenty-seven is the number of countries where this medium-sized German-based manufacturer has been able to license selenase since its founding in 1984. This global leader in selenium products is not stopping there, but will continue to drive innovation in the production of aseptic and high-quality trace element compounds under cleanroom conditions certified according to Current Good Manufacturing Practice regulations. Similarly, obtaining cGMP certification for the production facilities in 2009 was no mean feat either. Such certification of the manufacture of dietary supplements is not issued until the regulatory authorities have extensively analyzed materials and facilities.

By continuing to pursue its globalization strategy, biosyn aims to add many more countries to its list of markets for its pharmaceuticals and immunity-supportive dietary supplements manufactured by its proprietary and patented production method.

  1. cGMP
  2. global strategy
  3. micronutrients